MannKind (NASDAQ:MNKD) Getting Somewhat Positive Media Coverage, Analysis Shows

Media stories about MannKind (NASDAQ:MNKD) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MannKind earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.9681238075744 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

MannKind (MNKD) opened at $2.51 on Thursday. The company has a debt-to-equity ratio of -0.43, a current ratio of 0.31 and a quick ratio of 0.28. MannKind has a 1 year low of $0.67 and a 1 year high of $6.96. The company has a market cap of $288.33, a P/E ratio of -9.30 and a beta of 3.08.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.11). MannKind had a negative net margin of 155.83% and a negative return on equity of 24.93%. The business had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $2.56 million. During the same period in the prior year, the business earned $1.30 EPS. The business’s quarterly revenue was down 98.7% on a year-over-year basis. equities research analysts forecast that MannKind will post -1.13 earnings per share for the current fiscal year.

MNKD has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating on shares of MannKind in a research note on Wednesday, November 8th. Maxim Group reaffirmed a “hold” rating on shares of MannKind in a research report on Wednesday, November 1st. Zacks Investment Research cut shares of MannKind from a “hold” rating to a “sell” rating in a research report on Wednesday, December 13th. BidaskClub cut shares of MannKind from a “hold” rating to a “sell” rating in a research report on Friday, December 22nd. Finally, ValuEngine cut shares of MannKind from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Four research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $0.92.

In other news, VP Stuart A. Tross acquired 39,840 shares of MannKind stock in a transaction dated Thursday, December 21st. The shares were acquired at an average cost of $2.52 per share, for a total transaction of $100,396.80. Following the acquisition, the vice president now owns 59,840 shares of the company’s stock, valued at $150,796.80. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.10% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with's FREE daily email newsletter.

Leave a Reply